Abstract
INTRODUCTION: The prevalence of maxillary mucormycosis has surged in the wake of the COVID-19 pandemic. This study assesses the effectiveness of zygomatic implants and patient-specific 3D-manufactured implants in maxillary reconstruction post-mucormycosis secondary to COVID-19. METHODOLOGY: Ten patients underwent surgical and prosthetic maxillary reconstruction utilizing zygomatic implants and patient-specific implants. Parameters including pain, implant exposure, infection, wound dehiscence, implant fit, post-operative surgical rating scale, oro-antral communication, facial edema, and orbital status were evaluated at baseline, 6 months, and 12 months post-surgery. RESULTS: Statistical analysis revealed a positive association using SPSS version 20. Zygomatic implants combined with patient-specific implant systems demonstrated efficient therapeutic outcomes for maxillary reconstruction, within the limitations of the study. CONCLUSION: The study concludes that the integration of patient-specific implant systems with zygomatic implants offers a promising therapeutic approach for maxillary reconstruction post-mucormycosis secondary to COVID-19. However, further research with larger sample sizes and extended follow-up periods is warranted to validate these findings. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12663-024-02177-6.